Clinical Trial Update: Docetaxel+Oxali+/-Cetux Met Gastric/GEJ [Phase 2]

View source ↗

Summary

Phase 2 trial assessed docetaxel plus oxaliplatin, with or without cetuximab, in metastatic gastric/GEJ adenocarcinoma; results were posted in February 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: US Oncology Research | Conditions: Gastric Cancer Adenocarcinoma Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2016-02-11